United Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. 

CEO
Martine A. Rothblatt
CEOMartine A. Rothblatt
Employees
1,305
Employees1,305
Headquarters
Silver Spring, Maryland
HeadquartersSilver Spring, Maryland
Founded
1996
Founded1996
Employees
1,305
Employees1,305

UTHR Key Statistics

Market cap
20.01B
Market cap20.01B
Price-Earnings ratio
17.52
Price-Earnings ratio17.52
Dividend yield
Dividend yield
Average volume
491.94K
Average volume491.94K
High today
High today
Low today
Low today
Open price
$459.43
Open price$459.43
Volume
0.00
Volume0.00
52 Week high
$479.50
52 Week high$479.50
52 Week low
$266.98
52 Week low$266.98

Stock Snapshot

With a market cap of 20.01B, United Therapeutics(UTHR) trades at $462.30. The stock has a price-to-earnings ratio of 17.52.

On 2025-11-14, United Therapeutics(UTHR) shares started trading at $459.43, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 491.94K.

Over the past 52 weeks, United Therapeutics(UTHR) stock has traded between a high of $479.50 and a low of $266.98.

Over the past 52 weeks, United Therapeutics(UTHR) stock has traded between a high of $479.50 and a low of $266.98.

UTHR News

Simply Wall St 22h
How United Therapeutics' First UKidney Transplant Could Shape Innovation and Growth Prospects

United Therapeutics recently announced the first clinical xenotransplantation in its EXPAND study, where a UKidney™ was successfully transplanted into a patient...

How United Therapeutics' First UKidney Transplant Could Shape Innovation and Growth Prospects

Analyst ratings

69%

of 16 ratings
Buy
68.8%
Hold
31.3%
Sell
0%

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.